Growth Metrics

Armata Pharmaceuticals (ARMP) Restructuring Costs (2024 - 2026)

Quarterly results put Restructuring Costs at $2.0 million for Q1 2026, up 8.05% from a year ago — trailing twelve months through Mar 2026 was $7.7 million (down 2.49% YoY), and the annual figure for FY2025 was $7.5 million, down 8.93%.

Armata Pharmaceuticals has reported Restructuring Costs over the past 3 years, most recently at $2.0 million for Q1 2026.

  • Restructuring Costs reached $2.0 million in Q1 2026 per ARMP's latest filing, down from $2.3 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $2.3 million in Q4 2025 and bottomed at $1.4 million in Q2 2025.
  • Median Restructuring Costs over the past 3 years was $2.0 million (2024), compared with a mean of $2.0 million.
  • The largest annual shift saw Restructuring Costs fell 23.55% in 2025 before it rose 8.05% in 2026.
  • Over 3 years, Restructuring Costs stood at $2.2 million in 2024, then grew by 4.43% to $2.3 million in 2025, then dropped by 11.54% to $2.0 million in 2026.
  • Business Quant data shows Restructuring Costs for ARMP at $2.0 million in Q1 2026, $2.3 million in Q4 2025, and $2.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Armata Pharmaceuticals 301.92 Mn 297.17 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 2.00 Mn
Dec 31, 2025 2.26 Mn
Sep 30, 2025 1.97 Mn
Jun 30, 2025 1.43 Mn
Mar 31, 2025 1.85 Mn
Dec 31, 2024 2.17 Mn
Sep 30, 2024 1.97 Mn
Jun 30, 2024 1.87 Mn
Mar 31, 2024 2.24 Mn